Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
Brown DL, Levine DA, Albright K, Kapral MK, Leung LY, Reeves MJ, Sico J, Strong B, Whiteley WN, Council O. Benefits and Risks of Dual Versus Single Antiplatelet Therapy for Secondary Stroke Prevention: A Systematic Review for the 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke 2021, 52: e468-e479. PMID: 34024115, DOI: 10.1161/str.0000000000000377.Peer-Reviewed Original ResearchMeSH KeywordsDual Anti-Platelet TherapyHumansIschemic Attack, TransientPlatelet Aggregation InhibitorsPractice Guidelines as TopicRandomized Controlled Trials as TopicRisk AssessmentSecondary PreventionStrokeConceptsDual antiplatelet therapySingle antiplatelet therapyTransient ischemic attackHigh-risk transient ischemic attackIschemic stroke preventionRecurrent ischemic strokeIschemic attackIschemic strokeAntiplatelet therapyStroke preventionMajor bleedingRelative riskTreatment durationAmerican Heart Association/American Stroke AssociationSystematic reviewSecondary ischemic stroke preventionSecondary stroke preventionPrevention of strokeUnadjusted relative riskAmerican Stroke AssociationSecondary ischemic strokeDuration of treatmentLonger duration treatmentShort-duration trialsRecurrent stroke